Ashling Wahner

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.

Postmenopausal patients with ovarian or endometrial cancer who received conjugated equine estrogen may have increased mortality rates.

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.